Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 4/20 | 0.33 |
| ▸ | ANPEP | P15144 | 4/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F7 | P08709 | 1/20 | 0.33 |
| ▸ | F3 | P13726 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.33 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11964111 | 1.00 | ADRB3 (0.41) | ADRB3KMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL11964114 | 0.82 | ADRB3 (0.44) | ADRB3KMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL10189486 | 0.82 | ADRB3 (0.44) | ADRB3KMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL29143357 | 0.82 | ADRB3 (0.42) | ADRB3SMN1; SMN2F2F7F3 | |
| SCHEMBL29143356 | 0.82 | ADRB3 (0.42) | ADRB3SMN1; SMN2F2F7F3 | |
| SCHEMBL30148124 | 0.81 | ADRB3 (0.41) | ADRB3KMT2AKDM4EMEN1F2 | |
| SCHEMBL31264968 | 0.81 | ADRB3 (0.43) | ADRB3KMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL16188164 | 0.80 | ADRB3 (0.41) | ADRB3SMN1; SMN2F2F7F3 | |
| SCHEMBL31119161 | 0.79 | ADRB3 (0.40) | ADRB3 | |
| SCHEMBL30715263 | 0.76 | LMNA (0.41) | KMT2ASMN1; SMN2MEN1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117756809-A | Synthesis method of (6S) 4,6,7, 8-tetrahydro-4-oxo pyrrolo [1,2-A ] pyrimidine-6-carboxylic acid methyl ester | 苏州莱克施德药业有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-117756809-A | Synthesis method of (6S) 4,6,7, 8-tetrahydro-4-oxo pyrrolo [1,2-A ] pyrimidine-6-carboxylic acid methyl ester | 苏州莱克施德药业有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-117756809-A | Synthesis method of (6S) 4,6,7, 8-tetrahydro-4-oxo pyrrolo [1,2-A ] pyrimidine-6-carboxylic acid methyl ester | 苏州莱克施德药业有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-117756809-A | Synthesis method of (6S) 4,6,7, 8-tetrahydro-4-oxo pyrrolo [1,2-A ] pyrimidine-6-carboxylic acid methyl ester | 苏州莱克施德药业有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-11091493-B2 | Process for preparing beta 3 agonists and intermediates | MERCK SHARP & DOHME CORP. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200392141-A1 | PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES | MERCK SHARP & DOHME CORP. | 2020-12-17 | — | — | US | disclosed |
| EP-2968269-B1 | PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES | MERCK SHARP & DOHME (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10287289-B2 | Process for preparing beta 3 agonists and intermediates | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20170145014-A1 | PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES | MERCK SHARP & DOHME CORP. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20120258963-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2012-10-11 | — | — | US | disclosed |
| US-20120202819-A1 | COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONISTS AND AN ANTIMUSCARINIC AGENT | MERCK SHARP & DOHME CORPORATION (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2012012314-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2011043942-A1 | COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONIST AND AN ANTIMUSCARINIC AGENT | MERCK SHARP & DOHME CORP. (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110028481-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2011-02-03 | — | — | US | disclosed |
| WO-2009124166-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2009-10-08 | — | — | US | disclosed |
| WO-2009124167-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028481-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885KMT2A 2315/4885KDM4E 1791/4885 |
| US-20120258963-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885KMT2A 2315/4885KDM4E 1791/4885 |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885KMT2A 2315/4885KDM4E 1791/4885 |
| US-11091493-B2 | Process for preparing beta 3 agonists and intermediates | ADRB3, ADRA1D, ADRB1 | ADRB3 1/4885KMT2A 3639/4885KDM4E 2348/4885 |
| US-20200392141-A1 | PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES | ADRB3, ADRA1D, ADRB1 | ADRB3 1/4885KMT2A 3769/4885KDM4E 2488/4885 |
| US-20120202819-A1 | COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONISTS AND AN ANTIMUSCARINIC AGENT | ADRB2, ADRB3, ADRA2A | ADRB3 2/4885KMT2A 2088/4885KDM4E 4364/4885 |
| US-10287289-B2 | Process for preparing beta 3 agonists and intermediates | ADRB3, ADRA1D, ADRB1 | ADRB3 1/4885KMT2A 3769/4885KDM4E 2488/4885 |
| US-20170145014-A1 | PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES | ADRB3, ADRA1D, ADRB1 | ADRB3 1/4885KMT2A 3449/4885KDM4E 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.